Vol 28, No 1 (2023)
Letter to the Editor
Published online: 2023-02-14

open access

Page views 2081
Article views/downloads 261
Get Citation

Connect on Social Media

Connect on Social Media

letter to the editor

Reports of Practical Oncology and Radiotherapy

2023, Volume 28, Number 1, pages: 135–135

DOI: 10.5603/RPOR.a2023.0011

Submitted: 18.12.2022

Accepted: 06.02.2023

© 2023 Greater Poland Cancer Centre.

Published by Via Medica.

All rights reserved.

e-ISSN 2083–4640

ISSN 1507–1367

Comment on “telomerase reverse transcriptase rs2736098 and rs2736100 in bladder cancer”

Rujittika Mungmunpuntipantip1Viroj Wiwanitkit2
1Private Academic Consultant, Bangkok, Thailand
2Honorary professor, Dr DY Patil Vidhyapeeth, Pune, India

Address for correspondence: Rujittika Mungmunpuntipantip, Private Academic Consultant, Bangkok, Thailand; e-mail: rujittika@gmail.com

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially

Dear Editor, we would like to share ideas on the publication Implications of risk conferred by 5p15.33 loci genetic variants; human telomerase reverse transcriptase rs2736098 and rs2736100 in predisposition of bladder cancer [1]. Anwar et al. sought to clarify the genetic basis for bladder cancer in two significant human telomerase reverse transcriptase (hTERT) gene variants, rs2736098 and rs2736100 [1]. Anwar et al. came to the conclusion that the polymorphic hTERT rs2736098 variant plays a critical role in conferring a significant risk to bladder cancer in our group. Additionally, the hTERT haplotypes CA and AG inhTERT may prove to be a useful tool for screening the bladder cancer risk [1]. We concur that the single nucleotide polymorphisms (SNPs) under investigation may influence cancer risk. It is important to keep in mind that there could be additional complicating variables. There are additional genetic variations that Anwar et al. did not examine but which could have a confounding effect on the results of the current investigation. These genetic polymorphisms include changes in the cyclophilin family peptidyl-prolyl cis-trans isomerase (CYP8), interleukin 8 (IL-8) (+781 C/T), and matrix metallopeptidase 2 (MMP-2) (–735 C/T) genes [2–3].

Conflict of interest

None declared.

References

  1. Anwar I, Pandith AA, Mir H, et al. Implications of risk conferred by 5p15.33 loci genetic variants; human telomerase reverse transcriptase rs2736098 and rs2736100 in predisposition of bladder cancer. Rep Pract Oncol Radiother. 2022; 27(5): 787–796, doi: 10.5603/RPOR.a2022.0082, indexed in Pubmed: 36523804.
  2. Qu W, Zhang F, Cheng Y, et al. The impact of genetic variants in the gene on bladder cancer susceptibility. Front Endocrinol (Lausanne). 2022; 13: 989030, doi: 10.3389/fendo.2022.989030, indexed in Pubmed: 36246885.
  3. Alkanli N, Ay A, Cevik G. Investigation of roles of IL-8 (+ 781 C/T) and MMP-2 (-735 C/T) gene variations in early diagnosis of bladder cancer and progression. Mol Biol Rep. 2023; 50(1): 443–451, doi: 10.1007/s11033-022-07881-5, indexed in Pubmed: 36348195.